DNA
Ginkgo Bioworks Holdings, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 9 ▼ Four insiders, including executives and a 10% owner, sold $2.52M in…
- Apr 9 ▼ Three corporate insiders at Ginkgo Bioworks (DNA) conducted open-mar…
- Apr 10 to Apr 17 ▼ 3 days of insider sells: $1.0M by 2 insiders, avg $6.43
- May 22 ▼ 1 insider sell $2.6K at $8.33
- Jul 17 ▼ 1 insider sell $5.9K at $7.90
- Aug 7 ▼ TD Cowen downgrades
- Aug 24 ▼ 1 insider sell $2.3K at $6.98
- Sep 15 ▼ 1 insider sell $35.4K at $7.08
- Oct 5 ▼ 1 insider sell $36.0K at $15.00
- Oct 19 ▼ 4 insiders sell $1.3M at $10.14
- Nov 5 ▲ Earnings: DNA Q3 2026 Earnings: EPS $-0.64 (+27.2% vs est)
Signal stack
Where each data set points today.
- InsidersBEARISH
5 insiders sold $2.4M.
- InstitutionsBULLISH
Q3 2026: 21 added (0 new), 11 trimmed or exited.
- AnalystsBEARISH
0 of 10 rate it Buy or better. Median target $8.00 (−6%).
- Short sellersSTEADY
Short interest +14.4% to 9.49M shares. 3.9 days to cover, ≈14.8% of shares.
- TrendDOWNTREND
18% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 9.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | $18.7M |
| BARCLAYS PLC | DOUBLED | $6.6M |
| DIMENSIONAL FUND ADVISORS LP | ADD | $6.1M |
| MORGAN STANLEY | ADD | $2.7M |
| Walleye Capital LLC | DOUBLED | $2.0M |
| FRANKLIN TEMPLETON INC | DOUBLED | $2.0M |
| PANAGORA ASSET MANAGEMENT INC | ADD | $1.8M |
| SIMPLEX TRADING, LLC | DOUBLED | $1.1M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
10 analystsPrice is inside the target range. Median implies −6%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 13, 2026 | TD Cowen MAINTAIN | Hold |
| Sep 4, 2026 | BTIG REITERATE | Sell |
| Aug 7, 2026 | TD Cowen DOWNGRADE | Hold |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Canton Barry 10%+ Owner Oct 19, 2026 | SELL | $190.7K |
Coen Steven P. See remarks Oct 19, 2026 | SELL | $7.8K |
Canton Barry 10%+ Owner Oct 19, 2026 | SELL | $226.9K |
Shetty Reshma P. See remarks Oct 19, 2026 | SELL | $226.9K |
Shetty Reshma P. See remarks Oct 19, 2026 | SELL | $190.7K |
Kelly Jason R See remarks Oct 19, 2026 | SELL | $463.4K |
Coen Steven P. See remarks Oct 16, 2026 | EXERCISE | 312 sh |
Canton Barry 10%+ Owner Oct 16, 2026 | EXERCISE | 10,619 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.82 | -$0.82–-$0.82 | No data | $22.8M |
| Next Q | -$1.05 | -$1.05–-$1.05 | No data | $22.1M |
| Current FY | -$3.20 | -$3.20–-$3.20 | +0.0% | $90.1M |
| Next FY | -$2.90 | -$2.90–-$2.90 | +9.7% | $96.9M |
Short side
FINRA· Oct 30, 2026SecBot reports
7 filings · 0 bullish · 2 bearish · 5 neutral- NEUTRAL 8-KNov 5, 2026
Ginkgo Bioworks reported Q3 2026 revenue of $28M (down 6% YoY but up from $20M in Q2), GAAP net…
The first autonomous lab sale to Novo and government contract wins (ARPA-H, NSF) signal commercial traction, but revenue remains below year-ago levels and cash burn continues. Monitor the pace of…
- NEUTRAL 8-KOct 29, 2026
Ginkgo Bioworks filed an 8-K announcing the date of its Q3 2026 earnings presentation and Q&A…
Monitor the November 5 presentation for Q3 revenue and cash burn trends, which are key for a pre-revenue biotech platform company with a $725M market cap and heavy insider selling in the prior month.
- NEUTRAL CLUSTEROct 21, 2026
Two insiders at Ginkgo Bioworks sold a combined $198K in open-market sales on October 19, 2026…
Insider selling is trivial relative to market cap and concentrated in a single day. No urgency or informational edge is implied. Monitor next quarterly filing for any change in insider ownership…
- NEUTRAL 144Oct 19, 2026
Steven P. Coen, an officer of Ginkgo Bioworks, filed a Form 144 notice of intent to sell 766 Class…
This is a routine tax-withholding sale by an officer following a vesting event. No signal of insider concern. Monitor for any larger discretionary insider sales in future filings.
All DNA filing & press-release reports (7)
- 8-K reportNov 5, 2026
- 8-K reportOct 29, 2026
- CLUSTER reportOct 21, 2026
- 144 reportOct 19, 2026
- 144 reportSep 15, 2026
- CLUSTER reportApr 9, 2026
- CLUSTER reportApr 9, 2026